4735.TWO AViTA Corporation
- Market cap
- TWD 1.35B
- P/E
- 5.9x
- P/B
- 1.22x
- ROE
- 29.8%
- Dividend yield
- 6.63%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4735.TWO undervalued?
Graham number4735.TWO trades 43.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AViTA Corporation fundamental analysis
No fundamental analysis for AViTA Corporation yet.
AViTA Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AViTA Corporation
AViTA Corporation engages in the research, development, manufacturing, and sales of home healthcare products. Its products include non-contact thermometer, infrared ear/forehead thermometer, infrared ear thermometer, wrist type blood pressure monitor, arm type blood pressure monitor, nasal aspirator, nebulizer, electronic breast pump, pulse oximeter, and electronic lice comb. AViTA Corporation was founded in 1996 and is headquartered in New Taipei City, Taiwan.
Full company profileAViTA Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AViTA Corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.13B | 1.33B | 1.25B | 2.60B | 2.33B | 1.20B | 879M | 927M | 936M | 977M |
| Gross Profit | 299M | 334M | 391M | 940M | 675M | 357M | 265M | 255M | 296M | 304M |
| Operating Income | 116M | 130M | 177M | 651M | 396M | 138M | 44.1M | 15.6M | 46.4M | 75.9M |
| EBITDA | 147M | 156M | 208M | 695M | 468M | 207M | 105M | 126M | 155M | 414M |
| Net Income | 103M | 98.8M | 131M | 520M | 315M | 101M | 42.7M | 57.9M | 93.2M | 337M |
| EPS | 3.18 | 3.16 | 3.92 | 15 | 8.65 | 2.75 | 1.17 | 1.67 | 2.42 | 8.74 |
| Balance Sheet | ||||||||||
| Total Assets | 982M | 1.08B | 1.04B | 2.53B | 1.69B | 1.34B | 1.24B | 1.19B | 1.35B | 1.80B |
| Total Liabilities | 537M | 656M | 516M | 1.62B | 743M | 427M | 351M | 353M | 359M | 674M |
| Shareholders' Equity | 445M | 423M | 525M | 909M | 952M | 911M | 888M | 838M | 996M | 1.13B |
| Cash & Short-term Investments | 165M | 263M | 278M | 588M | 365M | 453M | 540M | 434M | 267M | 238M |
| Total Debt | - | - | - | 474M | 300M | 77.3M | 46.2M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 161M | 108M | 232M | 406M | 237M | 490M | 212M | 193M | 64.5M | 58.4M |
| Capital Expenditure | 119M | 31.9M | 44.4M | 198M | 71.9M | 65.3M | 31.3M | 83.8M | 262M | 82.3M |
| Free Cash Flow | 40.9M | 74.6M | 187M | 208M | 165M | 425M | 181M | 109M | -198M | -23.9M |
| Ratios | ||||||||||
| ROE | 23.2% | 23.4% | 24.9% | 57.2% | 33.1% | 11.1% | 4.8% | 6.9% | 9.4% | 29.8% |
| ROA | 10.5% | 9.2% | 12.6% | 20.5% | 18.6% | 7.6% | 3.4% | 4.9% | 6.9% | 18.7% |
| Net Profit Margin | 9.1% | 7.4% | 10.5% | 20.0% | 13.6% | 8.4% | 4.9% | 6.2% | 10.0% | 34.5% |
| Debt to Equity | - | - | - | 0.52x | 0.31x | 0.08x | 0.05x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AViTA Corporation dividends
- Dividend yield
- 6.63%
- Forward dividend
- 6.00 TWD
- Payout ratio
- 96.2%
- Ex-dividend date
- Aug 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 89.6M | 2.33 | 96.2% |
| 2024 | TWD 15.6M | 0.45 | 26.9% |
| 2023 | TWD 54.9M | 1.50 | 128.5% |
| 2022 | TWD 91.9M | 2.50 | 90.9% |
| 2021 | TWD 299M | 8.19 | 94.7% |
| 2020 | TWD 317M | 8.94 | 61.0% |
| 2019 | TWD 71.6M | 2.14 | 54.7% |
| 2018 | TWD 73.0M | 2.34 | 73.9% |
| 2017 | TWD 65.2M | 2.01 | 63.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AViTA Corporation
- Insiders 42.64%
- Institutions 0.00%
- Public & others 57.36%
- Shares outstanding 38.5M
- Free float 20.9M
AViTA Corporation company profile
- Company name
- AViTA Corporation
- Ticker
- 4735.TWO
- ISIN
- TW0004735006
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No.78, Kwang-Fu Road, New Taipei City, Taiwan, 24158
- Phone
- 886 2 8512 1568
- Website
- avita.com.tw
About AViTA Corporation
AViTA Corporation engages in the research, development, manufacturing, and sales of home healthcare products. Its products include non-contact thermometer, infrared ear/forehead thermometer, infrared ear thermometer, wrist type blood pressure monitor, arm type blood pressure monitor, nasal aspirator, nebulizer, electronic breast pump, pulse oximeter, and electronic lice comb. AViTA Corporation was founded in 1996 and is headquartered in New Taipei City, Taiwan.
AViTA Corporation management
4- Mr. Qiang JiGM & Vice Chairman
- Mr. Zhong Jie ZhuangChief Financial Officer
- Qiu Gui ChenAccounting Supervisor
- Mr. Yang-Xing OuCTO and Senior VP of R&D